Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PPD's 3Q Revenues up 27% | Contract Pharma
Financial News

PPD’s 3Q Revenues up 27%

Clinical Development Services revenue up 26% and Laboratory Services revenue grew 29%.

PPD
3Q Revenues: $1.6 billion (+27%)
3Q Earnings: $169.0 million (earnings were $9.1 million 3Q20)
YTD Revenues: $4.5 billion (+36%)
YTD Earnings: $268.0 million (earnings were $58.1 million YTD20)
Comments: Net authorizations growth of 12.7% over third quarter 2020 to $1.4 billion, resulting in a net book-to-bill ratio of 1.19x on a historical basis Ending backlog growth of 20.3% over third quarter 2020 to $9.5 billion on a historical basis. Revenue for the quarter increased 26.5% to $1.6 billion, compared to $1.2 billion for the three months ended September 30, 2020. At the segment level, Clinical Development Services revenue of $1.3 billion up 26% and Laboratory Services revenue of $290.2 million grew 28.9%, each compared to the three months ended September 30, 2020. Revenue for the nine months ended September 30, 2021 increased 36.1% to $4.5 billion, compared to $3.3 billion for the nine months ended September 30, 2020. At the segment level, Clinical Development Services revenue of $3.7 billion up 36.9% and Laboratory Services revenue of $826.4 million grew 32.8%, each compared to the nine months ended September 30, 2020.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters